Skip to content

Prospective Cohort Study on the Comparison of Long-Term Toxicity and Efficacy of Adjuvant Radiotherapy Between Transvaginal Laparoscopic Surgery and Transabdominal Laparoscopic Surgery for Endometrial Cancer

Prospective Cohort Study on the Comparison of Long-Term Toxicity and Efficacy of Adjuvant Radiotherapy Between Transvaginal Laparoscopic Surgery and Transabdominal Laparoscopic Surgery for Endometrial Cancer

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600125187
Enrollment
Unknown
Registered
2026-05-22
Start date
2026-06-01
Completion date
Unknown
Last updated
2026-05-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Endometrical cancer

Interventions

Cohort A (vNOTES group):None
Cohort B (LPS group):None

Sponsors

Chengdu Women's and Children's Central Hospital
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1.Pathologically confirmed endometrial cancer (Stage I–III, mainly endometrioid carcinoma, with a small amount of non-endometrioid carcinoma included); 2.Aged 18–75 years, ECOG performance status score 0–2; normal laboratory test results including liver and renal function and routine blood tests, with no contraindications to surgery or radiotherapy; 3.Assessed as intermediatehigh risk or above based on clinicopathological features and molecular classification, meeting the indications for postoperative adjuvant radiotherapy; 4.Voluntarily chose either transvaginal laparoscopic surgery (vNOTES) or transabdominal laparoscopic surgery (LPS) and achieved R0 resection; 5.Voluntarily signed the informed consent form and understood the study content, risks and benefits.

Exclusion criteria

Exclusion criteria: 1.Patients with FIGO stage IV disease, or with distant metastasis or lymph node metastasis. 2.Patients with a history of other malignant tumors, or with uncontrolled underlying diseases such as severe cardiovascular and cerebrovascular diseases or diabetes. 3.Patients who have previously received pelvic radiotherapy, chemotherapy, or hormone therapy. 4.Patients who did not achieve R0 resection, or who developed severe postoperative complications resulting in radiotherapy delay of more than 4 weeks. 5.Pregnant or lactating women; or patients with mental illness, cognitive impairment, who are unable to comply with the study and follow-up.

Design outcomes

Primary

MeasureTime frame
Incidence rate of grade >= 2 late toxicities at 3 years;

Secondary

MeasureTime frame
Overall survival, OS;Progression-Free Survival, PFS;Acute toxicity incidence;Quality of Life (QoL) score;

Countries

China

Contacts

Public ContactYonghong Lin

Chengdu Women's and Children's Central Hospital

linyhcd2011@163.com+86 138 0803 1895

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: May 30, 2026